Month: June 2021

OIS Podcast Episode #270: KOLs Speak Out on the Future of Gene Therapy via @You…

OIS Podcast Episode #270: KOLs Speak Out on the Future of Gene Therapy https://t.co/nXMnR91Btg via @YouTube Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ModernRetina: @BauschLomb and Clearside Biomedical Inc. announced that the U…

RT @ModernRetina: @BauschLomb and Clearside Biomedical Inc. announced that the U.S. Food and Drug Administration (@US_FDA) has accepted the… Source by Thomas Ciulla, MD, MBA Return to main website.

Just published…Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib…


Just published…Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib Suspension Via Ocular and Systemic Disposition in Rabbits | TVST | ARVO Journals https://t.co/py84aPE3Ra

#retina #AMD #maculardegeneration #suprachoroidal #cls-ax


Source by Thomas Ciulla, MD, MBA

Return to main website.

Just published: “Suprachoroidal delivery of axitinib, combined with pan-VEGF in…

Just published: https://t.co/WYQcf8TY9n “Suprachoroidal delivery of axitinib, combined with pan-VEGF inhibition activity of axitinib, has the potential to provide additional benefits compared to the current standard of care with intravitreal anti–VEGF-A agents.” #retina #AMD Source by Thomas Ciulla, MD, MBA Return to main website.

Bausch Health And Clearside Biomedical Announce FDA Filing Acceptance For Xipere…

Bausch Health And Clearside Biomedical Announce FDA Filing Acceptance For Xipere on @EyeWireNews https://t.co/CefpnRcEbg Source by Thomas Ciulla, MD, MBA Return to main website.